Hospital Universitari Vall d'Hebron - Dept of Oncology

Barcelona 8035

0 studies enrolling now · 8 studies all time

What they study most

Biliary Tract Cancer, Cervical Cancer, Cholangiocarcinoma, Gallbladder Cancer, Locally Advanced Rectal Cancer, Non-small Cell Lung Cancer, Uterine Cervical Neoplasms

Studies at this site

• A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) — Running, not enrolling
• M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC) — Completed
• Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046) — Completed
• M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) — Stopped early
• Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC — Stopped early
• M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer) — Completed
• Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer — Completed
• Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer — Completed